Chinese B2B pharmaceutical trading and education platform Yaoshibang has received RMB420 million ($65 million) in Series C funding across two tranches.
A group of VCs including China Growth Capital have agreed to invest $16 million in Ono, a China-based company that claims to be the creator of the first decentralized social network.
M17 Entertainment, a Taiwan and Singapore-based media streaming company, has abandoned plans for a $60.1 million IPO in the US citing unspecified difficulties with some investors.
Australian medical device manufacturer Sirtex Medical has accepted a A$1.9 billion ($1.4 billion) buyout offer from China’s CDH Investments, pulling the plug on an earlier agreement with US-listed Varian Medical Systems.
Venture capital deals involving IDG Capital, Orchid Asia, Fosun Group, Matrix Partners, ZhenFund, Sky9 Capital, CDH Investments, Meridian Capital, Eastern Bell Venture Capital, SIG, and Qianhai FoF
China Growth Capital has led a $17.7 million Series A round of funding for Cheduoduo, a newly launched Chinese used car trading platform, with participation from Source Code Capital.
Yitu Technology, a Chinese artificial intelligence (AI) start-up that is developing solutions for machine vision, listening and understanding, has raised $200 million in Series C-plus funding.
Capital Group Private Markets (CGPM) has joined GP Capital to invest in Jinxin Healthcare, the maternity care division of Chinese hospital operator Chengdu Jinxin Healthcare Investment Management Group (Jinxin Group).
Byton, a China-based manufacturer of smart electric cars backed by Legend Capital, has secured a $500 million Series B funding round from a group of domestic strategic investors.
Jenny Wu, a managing partner at Baidu Capital, discusses growth stage investment in artificial intelligence
Hong Kong-based Beyond Ventures has joined a $10 million round for ePropulsion Innovation, a domestic technology developer focused on electric motors for recreational boating.
Pivotal BioVenture Partners China, an investment platform of Hong Kong conglomerate Nan Fung Group, has led a $16.5 million seed round for Sino-US cancer drug developer Oncologie.
Xiaomi, a private equity-backed Chinese smart phone maker that filed for a Hong Kong IPO last month, has become the first company to apply to issue Chinese Depository Receipts (CDRs).
Hua Medicine, a Chinese drug developer player that simultaneously closed its Series D and E funding rounds in March, has become the second company to file for a Hong Kong IPO under rules that allow zero revenue biotech businesses to go public.
Ant Financial, Alibaba Group’s financial services affiliate, has raised $14 billion in Series C funding from investors including GIC Private, Warburg Pincus, The Carlyle Group, Silver Lake, and Canada Pension Plan Investment Board (CPPIB).
Cornerstone Capital, a China-based PE firm that focuses on pre-IPO investments, has filed for an IPO on NASDAQ.
Two Chinese online used car trading platforms – Chezhibao and Tiantian Paiche (TTP) – have received a combined $225 million in funding, continuing the flood of private capital into the space.
Actis has appointed Ellen Li, formerly of Janus Henderson Global Investors, as a managing director and head of its investor development group in Asia.
Hong Kong-based VC firm Mandra Capital and Sina Corporation have led a $103 million funding round for Chinese financial technology platform Pintec.
Hangzhou Just Biotherapeutics (Just China), the Chinese joint venture of US drug developer Just Biotherapeutics, has received $35 million in Series B-plus funding led by Hillhouse Capital.
Tiger Global Management has led a $70 million Series B-plus funding round for Chinese start-up Danke Apartment, operator of an online platform that connects landlords with long-term rental tenants.
The complexity of a private equity firm’s key person clauses – and the number of people they encompass – says much about its institutionalization. The transition is not always easy, for GPs or LPs
Institutional investors are preparing for a downturn in Asia – and emphasizing the importance of disciplined deployment – as they see worrying “pro-cycle market behavior” in the private markets space globally.
Nan Fung Group has established Pivotal Bioventure Partners China to build a concentrated portfolio of high-quality life science assets and nurture them from inception to exit